Genetic
An integrated pharmaceutical company focused on the research, development, manufacturing, licensing and medical devices.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Secondary | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 10 % | 21 % | (34 %) | 59 % | 92 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 33 % | 47 % | 48 % | 32 % | 44 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 17 % | 27 % | 30 % | (44 %) | (14 %) | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Founded in 2000 by Rocco Pavese, Genetic S.p.A. operates as an international, research-focused pharmaceutical company based in Fisciano, Italy. The company functions as a Contract Development and Manufacturing Organization (CDMO), providing drug development, manufacturing services, and licensing for other pharmaceutical companies. Its business model is centered on a B2B approach, serving leading multinational pharmaceutical partners by offering expertise in process development, regulatory knowledge, and a controlled supply chain. Revenue is generated through the development, manufacturing, licensing, and promotion of pharmaceutical specialties and medical devices.
Genetic specializes in complex therapeutic areas, particularly respiratory, ophthalmology, and oncology. The company has developed a diverse portfolio of products, including preservative-free sterile solutions, eye drops, nasal sprays, and oral solids. It utilizes advanced manufacturing technologies like Blow-Fill-Seal for aseptic filling of single-dose units and produces pressurized Metered-Dose Inhalers (pMDI). The company operates two main production departments for liquid and solid oral forms, handling a wide range of substances from corticosteroids to cancer drugs. Their manufacturing plant, completed in 2006, is equipped for serialization and aggregation to ensure product traceability.
Rocco Pavese, the founder, continues to lead the company as CEO, with Francesca Pavese responsible for Business Development and Internationalization. Under their leadership, Genetic has expanded its international footprint from approximately 20 countries in 2020 to over 40. A significant milestone occurred in May 2025 when Renaissance Partners and Aurora Growth Capital acquired the company, with the Pavese family reinvesting to continue steering the company's expansion. This partnership aims to increase production capacity, including the construction of a new facility in Fisciano. The company is indirectly present in over 30 European and non-EU countries and serves major Italian and foreign pharmaceutical multinationals.
Keywords: CDMO, pharmaceutical manufacturing, contract development, respiratory therapies, ophthalmology drugs, oncology treatments, drug licensing, Blow-Fill-Seal technology, sterile solutions, pMDI, pharmaceutical development, medical devices, generic-plus, Rocco Pavese, Fisciano Italy, pharmaceutical B2B, drug delivery systems, aseptic filling, solid oral dosage, liquid pharmaceuticals